已发表论文

肺腺癌脑转移的积极治疗:埃克替尼 (Icotinib)


 

Authors Zhang Y, Tang HP, Li J, Li M

Published Date June 2015 Volume 2015:8 Pages 1351—1354

DOI http://dx.doi.org/10.2147/OTT.S78925

Received 9 December 2014, Accepted 15 April 2015, Published 8 June 2015

Approved for publication by Professor Daniele Santini

Abstract: Lung cancer has the highest mortality rate of all cancers world­wide. A total of 70%–75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year.
Keywords: EGFR, non-small cell lung cancer, tyrosine kinase inhibitor